Btc clinical trials

Explore recruiting btc clinical trials.

Recruiting btc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Btc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard of-care therapy alone for advanced HER2 positive biliary tract cancer

Germany, Belgium, Spain, Finland, Czechia, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

Norway, Italy, Poland, Spain, Belgium, Denmark +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

IMMUWHY - A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

TRAP-BTC Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)

Poland, Bulgaria, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Italy, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Btc trials by city

Btc in Toronto Btc in Vancouver Btc in Montreal Btc in Calgary Btc in Edmonton Btc in Ottawa Btc in Winnipeg Btc in Quebec City Btc in Hamilton Btc in Kitchener Btc in London Btc in Halifax Btc in New York Btc in Los Angeles Btc in Chicago Btc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease